Dasiglucagon is contraindicated in patients with pheochromocytoma or insulinoma.
See also the entry for glucagon.
- TRADE NAME: Zegalogue (Zealand Pharma)
- INDICATIONS: Treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
- HALF-LIFE: ~30 minutes
- FDA APPROVAL DATE: 03/22/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
beta-blockers, Indomethacin, Warfarin - PREGNANCY: No available data on dasiglucagon use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
